Brisbane, Queensland, Australia In 2002 was created QIC BioVentures, which is appeared as VC. The main office of represented VC is situated in the Brisbane. The fund was located in Australia.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the QIC BioVentures, startups are often financed by GBS Ventures, Uniseed Ventures, Westscheme Pty Limited. The meaningful sponsors for the fund in investment in the same round are GBS Ventures, Uniseed Ventures, Westscheme Pty Limited. In the next rounds fund is usually obtained by GBS Ventures, Uniseed Ventures, OneVentures.
The common things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2005. This QIC BioVentures works on 22 percentage points less the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2016.
The fund has exact preference in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Medical Device, Biotechnology. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Australia. Among the most popular portfolio startups of the fund, we may highlight Gelesis, Columna, Hatchtech.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Gelesis | $16M | 03 Jan 2008 | Boston, Massachusetts, United States | ||
Protagonist Therapeutics | $9M | 19 Sep 2006 | Queensland | ||
ConjuChem | $8M | 01 Aug 1999 | Los Angeles, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Gelesis | $16M | 03 Jan 2008 | Boston, Massachusetts, United States | ||
Protagonist Therapeutics | $9M | 19 Sep 2006 | Queensland | ||
ConjuChem | $8M | 01 Aug 1999 | Los Angeles, California, United States |
